durvalumab + osimertinib

Durvalumab + osimertinib is an investigational combination therapy for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Durvalumab is a high-affinity human IgG1 monoclonal antibody that blocks programmed death-ligand 1 (PD-L1) from binding to PD-1 and CD80, thereby enhancing anti-tumor immune responses. Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively targets both EGFR-sensitizing and T790M resistance mutations. The combination was evaluated in the TATTON phase 1b trial for patients with advanced EGFR-mutant NSCLC who had progressed on prior EGFR-TKI therapy or were treatment-naive. While the regimen showed encouraging clinical activity and tumor response rates, it was associated with a significantly increased risk of interstitial lung disease (ILD)-related adverse events compared to either agent alone[1][2].

Brand names

Tagrisso (for osimertinib)Imfinzi (for durvalumab)

Other names

durvalumab plus osimertinibosimertinib plus durvalumab